Supplemental Digital Content for Prot. C Dz Progression Paper

20 Feb 2013

Table 1: Cox proportional hazard models, East Africa only

Table 2: Cox proportional hazard models, Discordant Couples only

Table 3: Cox proportional hazard models, all males vs. females

Table 4: HLA type frequency and distribution by infecting subtype, most prevalent HLA types only

Table 5: Cox proportional hazard models of time to the endpoint of CD4 reaching < 350 cells/µL or ART initiation

Table 6: Month 3 CD4 counts in East Africa by infecting subtype and 3-tiered gender

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Digital Content Table 1. Cox proportional hazards models of time to event among cohort participants in East Africa with HLA**‡ **data (n=270)** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  |  |  | |  |  | | |  | | | |  |  | |  |  | |  | |  | |  | |  |  | |  |  | |  |  | |  | | |  |  | |
|  |  | Time to CD4 ≤ 350 cells/μL | | | | | | | | | | | | |  | Time to viral load ≥ 1x105 copies/ml | | | | | | | | | | |  | Time to AIDS^ | | | | | | | | | | |
|  |  | Unadjusted | | | | | | Adjusted | | | | | | |  | Unadjusted | | | | | Adjusted | | | | | |  | Unadjusted | | | | | Adjusted | | | | | |
|  | n | HR\* | 95% CI# | | | | p | HR | | 95% CI | | | p | |  | HR | 95% CI | | p | | HR | | 95% CI | | | p |  | HR | 95% CI | | | p | HR | | 95% CI | | | p |
|  |  |  |  | | | |  |  | |  | | |  | |  |  |  | |  | |  | |  | | |  |  |  |  | | |  |  | |  | | |  |
| Age at EDI\*\* (years) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <40 | 232 | 1 |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| ≥ 40 | 38 | 1.50 | (0.91, 2.47) | | | 0.114 | | | 1.47 | | (0.88, 2.45) | | | 0.145 |  | 2.02 | (1.22, 3.36) | | 0.007 | | 1.83 | | (1.10, 3.07) | | | 0.021 |  | 1.23 | (0.69, 2.18) | | | 0.481 | | 1.15 | (0.65, 2.05) | | | 0.631 |
|  |  |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Sex | |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Female | 98 | 1 |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Male | 172 | 1.44 | (0.94, 2.20) | | | 0.096 | | | 1.41 | | (0.91, 2.18) | | | 0.126 |  | 1.92 | (1.18, 3.10) | | 0.008 | | 1.85 | | (1.13, 3.04) | | | 0.014 |  | 1.61 | (1.01, 2.57) | | | 0.044 | | 1.73 | (1.08, 2.77) | | | 0.024 |
|  |  |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HLA B\*57 allele | | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| No | 251 | 1 |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Yes | 19 | 0.29 | (0.09, 0.91) | | | 0.034 | | | 0.27 | | (0.09, 0.87) | | | 0.028 |  | 0.65 | (0.26, 1.61) | | 0.354 | | 0.67 | | (0.27, 1.67) | | | 0.387 |  | 0.33 | (0.10, 1.05) | | | 0.061 | | 0.34 | (0.11, 1.09) | | | 0.069 |
|  |  |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HLA B\*45 allele | | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| No | 226 | 1 |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Yes | 44 | 1.80 | (1.13, 2.87) | | | 0.014 | | | 1.61 | | (1.00, 2.59) | | | 0.048 |  | 2.14 | (1.32, 3.47) | | 0.002 | | 2.27 | | (1.36, 3.80) | | | 0.002 |  | 1.53 | (0.89, 2.63) | | | 0.128 | | 1.49 | (0.86, 2.58) | | | 0.160 |
|  |  |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HIV-1 Subtype | |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| A | 177 | 1 |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| C | 22 | 1.15 | (0.57, 2.31) | | | 0.699 | | | 1.12 | | (0.55, 2.25) | | | 0.761 |  | 1.09 | (0.50, 2.41) | | 0.823 | | 1.17 | | (0.53, 2.59) | | | 0.700 |  | 1.27 | (0.57, 2.81) | | | 0.558 | | 1.17 | (0.53, 2.61) | | | 0.693 |
| D | 71 | 1.05 | (0.67, 1.65) | | | 0.834 | | | 1.02 | | (0.64, 1.63) | | | 0.934 |  | 1.53 | (0.97, 2.41) | | 0.065 | | 1.83 | | (1.12, 2.98) | | | 0.015 |  | 1.75 | (1.11, 2.76) | | | 0.016 | | 1.77 | (1.11, 2.82) | | | 0.016 |
|  |  |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
|  |  |  |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |

‡HLA, Human Leukocyte Antigen.

^1993 CDC Case Definition; majority of endpoints were CD4 < 200 cells/µl.

\*HR, Hazard Ratio.

#CI, Confidence Interval.

\*\*EDI, Estimated date of infection.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Digital Content Table 2. Cox proportional hazards models of time to event among cohort participants from discordant couples with HLA**‡ **data (n=380)** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  |  |  | | |  |  | | |  | | | |  |  | |  |  | |  | |  | |  | |  |  | |  |  | |  |  | |  | | |  |  | |
|  |  | Time to CD4 ≤ 350 cells/ μL | | | | | | | | | | | | | |  | Time to viral load ≥ 1x105 copies/ml | | | | | | | | | | |  | Time to AIDS^ | | | | | | | | | | |
|  |  | Unadjusted | | | | | | | Adjusted | | | | | | |  | Unadjusted | | | | | Adjusted | | | | | |  | Unadjusted | | | | | Adjusted | | | | | |
|  | n | HR\* | 95% CI# | | | | | p | HR | | 95% CI | | | p | |  | HR | 95% CI | | p | | HR | | 95% CI | | | p |  | HR | 95% CI | | | p | HR | | 95% CI | | | p |
|  |  |  |  | | | | |  |  | |  | | |  | |  |  |  | |  | |  | |  | | |  |  |  |  | | |  |  | |  | | |  |
| Age at EDI\*\* (years) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| < 40 | 312 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| ≥ 40 | 68 | 1.32 | | (0.91, 1.92) | | | 0.150 | | | 1.25 | | (0.84, 1.84) | | | 0.268 |  | 1.26 | (0.86, 1.86) | | 0.223 | | 1.08 | | (0.73, 1.60) | | | 0.711 |  | 1.26 | (0.83, 1.93) | | | 0.278 | | 1.25 | (0.81, 1.94) | | | 0.304 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Sex | |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Female | 170 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Male | 210 | 1.34 | | (0.98, 1.84) | | | 0.065 | | | 1.27 | | (0.92, 1.76) | | | 0.144 |  | 2.03 | (1.44, 2.86) | | <.001 | | 1.97 | | (1.39, 2.80) | | | <.001 |  | 1.39 | (0.96, 2.00) | | | 0.080 | | 1.33 | (0.91, 1.94) | | | 0.145 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HLA B\*57 allele | | | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| No | 347 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Yes | 33 | 0.72 | | (0.40, 1.29) | | | 0.268 | | | 0.71 | | (0.39, 1.29) | | | 0.258 |  | 0.38 | (0.18, 0.82) | | 0.013 | | 0.39 | | (0.18, 0.84) | | | 0.016 |  | 0.19 | (0.06, 0.61) | | | 0.005 | | 0.19 | (0.06, 0.60) | | | 0.005 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HLA B\*45 allele | | | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| No | 328 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Yes | 52 | 1.74 | | (1.17, 2.60) | | | 0.006 | | | 1.56 | | (1.04, 2.34) | | | 0.031 |  | 1.61 | (1.06, 2.43) | | 0.026 | | 1.42 | | (0.93, 2.17) | | | 0.109 |  | 1.26 | (0.76, 2.09) | | | 0.361 | | 1.15 | (0.69, 1.91) | | | 0.597 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HIV-1 Subtype | |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| A | 108 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| C | 228 | 1.73 | | (1.20, 2.50) | | | 0.004 | | | 1.73 | | (1.19, 2.50) | | | 0.004 |  | 1.52 | (1.03, 2.24) | | 0.035 | | 1.52 | | (1.03,2.34) | | | 0.037 |  | 2.00 | (1.26, 3.18) | | | 0.003 | | 1.96 | (1.24, 3.12) | | | 0.004 |
| D | 44 | 0.82 | | (0.43,1.57) | | | 0.549 | | | 0.81 | | (0.42, 1.55) | | | 0.522 |  | 1.72 | (0.98, 3.03) | | 0.057 | | 1.60 | | (0.90, 2.83) | | | 0.103 |  | 2.15 | (1.12, 4.14) | | | 0.021 | | 1.91 | (0.99, 3.68) | | | 0.054 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |

‡HLA, Human Leukocyte Antigen.

^1993 CDC Case Definition; majority of endpoints were CD4 < 200 cells/µl.

\*HR, Hazard Ratio.

#CI, Confidence Interval.

\*\*EDI, estimated date of infection.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Digital Content Table 3. Cox proportional hazards models of time to event among cohort participants with HLA**‡ **data comparing all males to females (n=491)** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  |  |  | | |  |  | | |  | | | |  |  | |  |  | |  | |  | |  | |  |  | |  |  | |  |  | |  | | |  |  | |
|  |  | Time to CD4 ≤ 350 cells/ μL | | | | | | | | | | | | | |  | Time to viral load ≥ 1x105 copies/ml | | | | | | | | | | |  | Time to AIDS^ | | | | | | | | | | |
|  |  | Unadjusted | | | | | | | Adjusted | | | | | | |  | Unadjusted | | | | | Adjusted | | | | | |  | Unadjusted | | | | | Adjusted | | | | | |
|  | n | HR\* | 95% CI# | | | | | p | HR | | 95% CI | | | p | |  | HR | 95% CI | | p | | HR | | 95% CI | | | p |  | HR | 95% CI | | | p | HR | | 95% CI | | | p |
|  |  |  |  | | | | |  |  | |  | | |  | |  |  |  | |  | |  | |  | | |  |  |  |  | | |  |  | |  | | |  |
| Age at EDI\*\* (years) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <40 | 416 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| ≥ 40 | 75 | 1.46 | | (1.04, 2.05) | | | 0.031 | | | 1.36 | | (0.96, 1.93) | | | 0.086 |  | 1.40 | (0.97, 2.01) | | 0.072 | | 1.17 | | (0.81, 1.70) | | | 0.394 |  | 1.40 | (0.96, 2.04) | | | 0.081 | | 1.29 | (0.88, 1.90) | | | 0.188 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Sex | |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Female | 200 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Male | 291 | 1.36 | | (1.02, 1.81) | | | 0.034 | | | 1.30 | | (0.97, 1.74) | | | 0.077 |  | 1.97 | (1.43, 2.71) | | <.001 | | 1.99 | | (1.44, 2.76) | | | <.001 |  | 1.52 | (1.10, 2.09) | | | 0.011 | | 1.51 | (1.08, 2.10) | | | 0.014 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HLA B\*57 allele | | | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| No | 450 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Yes | 41 | 0.60 | | (0.34, 1.05) | | | 0.072 | | | 0.60 | | (0.34, 1.06) | | | 0.080 |  | 0.38 | (0.19, 0.78) | | 0.008 | | 0.39 | | (0.19, 0.80) | | | 0.010 |  | 0.30 | (0.13, 0.68) | | | 0.004 | | 0.30 | (0.13, 0.68) | | | 0.004 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| HLA B\*45 allele | | | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| No | 415 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| Yes | 76 | 1.71 | | (1.22, 2.39) | | | 0.002 | | | 1.59 | | (1.14, 2.24) | | | 0.007 |  | 1.58 | (1.10, 2.27) | | 0.013 | | 1.43 | | (0.99, 2.08) | | | 0.057 |  | 1.48 | (0.99, 2.20) | | | 0.053 | | 1.37 | (0.92, 2.05) | | | 0.124 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| Subtype |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
| A | 177 | 1 | |  | | |  | | | 1 | |  | | |  |  | 1 |  | |  | | 1 | |  | | |  |  | 1 |  | | |  | | 1 |  | | |  |
| C | 243 | 1.58 | | (1.16, 2.14) | | | 0.003 | | | 1.62 | | (1.19, 2.20) | | | 0.002 |  | 1.57 | (1.13, 2.19) | | 0.008 | | 1.71 | | (1.22,2.39) | | | 0.002 |  | 1.41 | (0.99, 2.00) | | | 0.054 | | 1.42 | (1.00, 2.02) | | | 0.047 |
| D | 71 | 1.05 | | (0.67,1.65) | | | 0.837 | | | 1.05 | | (0.66, 1.66) | | | 0.838 |  | 1.46 | (1.00, 2.46) | | 0.052 | | 1.70 | | (1.07, 2.70) | | | 0.025 |  | 1.81 | (1.15, 2.85) | | | 0.011 | | 1.76 | (1.12, 2.79) | | | 0.015 |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |
|  |  |  | |  | | |  | | |  | |  | | |  |  |  |  | |  | |  | |  | | |  |  |  |  | | |  | |  |  | | |  |

‡HLA, Human Leukocyte Antigen.

^1993 CDC Case Definition; majority of endpoints were CD4 < 200 cells/µl.

\*HR, Hazard Ratio.

#CI, Confidence Interval.

\*\*EDI, Estimated date of infection.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Digital Content Table 4. Frequency and percentage of cohort participants by HLA‡ type and HIV-1 infecting subtype for the most prevalent HLA types. | | | | | | | | | |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  | **HIV-1 Subtype** | | | | | |  |
|  | **Total (n=495)** | | **A (n=179)** | | **C (n=245)** | | **D (n=71)** | |  |
|  |  |
| **HLA** | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** | ***p*-value1** |
|  |  |  |  |  |  |  |  |  |  |
| **A\*30** | 175 | 35.4 | 57 | 31.8 | 101 | 41.2 | 17 | 23.9 | 0.013 |
| **A\*02** | 171 | 34.5 | 78 | 43.6 | 64 | 26.1 | 29 | 40.8 | <0.001 |
| **A\*68** | 112 | 22.6 | 45 | 25.1 | 46 | 18.8 | 21 | 29.6 | 0.096 |
| **A\*23** | 78 | 15.8 | 19 | 10.6 | 51 | 20.8 | 8 | 11.3 | 0.009 |
| **A\*74** | 60 | 12.1 | 28 | 15.6 | 29 | 11.8 | 3 | 4.2 | NA |
| **A\*01** | 55 | 11.1 | 29 | 16.2 | 11 | 4.5 | 15 | 21.1 | <0.001 |
| **A\*29** | 50 | 10.1 | 13 | 7.3 | 31 | 12.7 | 6 | 8.5 | 0.169 |
| **A\*03** | 49 | 9.9 | 17 | 9.5 | 22 | 9 | 10 | 14.1 | 0.436 |
| **A\*36** | 45 | 9.1 | 13 | 7.3 | 24 | 9.8 | 8 | 11.3 | 0.528 |
| **A\*34** | 39 | 7.9 | 7 | 3.9 | 24 | 9.8 | 8 | 11.3 | 0.044 |
|  |  |  |  |  |  |  |  |  |  |
| **B\*15** | 167 | 33.7 | 56 | 31.3 | 85 | 34.7 | 26 | 36.6 | 0.655 |
| **B\*53** | 93 | 18.8 | 30 | 16.8 | 47 | 19.2 | 16 | 22.5 | 0.560 |
| **B\*5802** | 75 | 15.2 | 36 | 20.1 | 28 | 11.4 | 11 | 15.5 | 0.096 |
| **B\*45** | 76 | 15.4 | 34 | 19 | 35 | 14.3 | 7 | 9.9 | 0.158 |
| **B\*42** | 65 | 13.1 | 22 | 12.3 | 35 | 14.3 | 8 | 11.3 | 0.736 |
| **B\*07** | 63 | 12.7 | 23 | 12.8 | 28 | 11.4 | 12 | 16.9 | 0.475 |
| **B\*44** | 55 | 11.1 | 17 | 9.5 | 32 | 13.1 | 6 | 8.5 | 0.382 |
| **B\*5801** | 55 | 11.1 | 20 | 11.2 | 29 | 11.8 | 6 | 8.5 | 0.726 |
| **B\*14** | 48 | 9.7 | 14 | 7.8 | 27 | 11 | 7 | 9.9 | 0.546 |
| **B\*57** | 41 | 8.3 | 15 | 8.4 | 23 | 9.4 | 3 | 4.2 | NA |
|  |  |  |  |  |  |  |  |  |  |
|  | | | | | | | | | |

1When the frequency of an allele is less than 5, the p-value is inaccurate.

‡HLA, Human Leukocyte Antigen.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Supplemental Digital Content Table 5. Hazard Ratios (HRs) for time to CD4 ≤ 350 cells/µL or initiation of antiretroviral therapy from estimated date of HIV-1 Infection (EDI) (n = 491) | | | | | | | |
|  |  |  | | |  | | |
|  |  | **Unadjusted Analysis** | | | **Adjusted Analysis** | | |
| **Characteristic** | **n** | **HR\*** | **95% CI** | ***p*-value** | **HR** | **95% CI** | ***p*-value** |
|  |  |  |  |  |  |  |  |
| **Age at EDI^ (years)** | | |  |  |  |  |  |
| **< 40** | 416 | 1 |  |  | 1 |  |  |
| **≥ 40** | 75 | 1.28 | (0.91, 1.78) | 0.152 | 1.21 | (0.85, 1.72) | 0.286 |
|  |  |  |  |  |  |  |  |
| **Gender** |  |  |  |  |  |  |  |
| **Female** | 200 | 1 |  |  | 1 |  |  |
| **Non-MSM#** | 232 | 1.19 | (0.91, 1.56) | 0.201 | 1.13 | (0.85, 1.49) | 0.399 |
| **MSM** | 59 | 0.94 | (0.60, 1.47) | 0.783 | 1.02 | (0.64, 1.63) | 0.943 |
|  |  |  |  |  |  |  |  |
| **HLA‡ B\*57 allele** | | | | | | | |
| **No** | 450 | 1 |  |  | 1 |  |  |
| **Yes** | 41 | 0.55 | (0.32, 0.95) | 0.032 | 0.57 | (0.33, 0.98) | 0.044 |
|  |  |  |  |  |  |  |  |
| **HLA B\*45 allele** | | | | | | | |
| **No** | 415 | 1 |  |  | 1 |  |  |
| **Yes** | 76 | 1.66 | (1.21, 2.28) | 0.002 | 1.61 | (1.17, 2.22) | 0.003 |
|  |  |  |  |  |  |  |  |
| **HIV-1 subtype** |  |  |  |  |  |  |  |
| **A** | 177 | 1 |  |  | 1 |  |  |
| **C** | 243 | 1.47 | (1.10, 1.95) | 0.008 | 1.47 | (1.09, 1.97) | 0.011 |
| **D** | 71 | 1.21 | (0.81, 1.80) | 0.361 | 1.18 | (0.78, 1.78) | 0.426 |
|  |  |  |  |  |  |  |  |
|  | | | | | | | |

\*HR, Hazard Ratio.

^EDI, Estimated date of infection.

#MSM, men who have sex with men.

‡HLA, Human Leukocyte Antigen.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplemental Digital Content Table 6. CD4 count values at month 3\* by HIV-1 infecting subtype and gender among participants in East Africa (n=576) | | | | | | | | | |
|  |  |  |  |  | |  |  |  |
|  |  | **HIV-1 Subtype** | | | | | |  |
| **Gender** |  | **Total** | **A** | | **C** | **D** | **Other+** | ***P-value*** |
| **All** | n | 233 | 139 | | 17 | 59 | 18 | 0.716 |
|  | Median  (cells/µL) | 576 | 595 | | 548 | 557 | 594 |  |
|  | IQR#  (cells/µL) | 452-716 | 453-730 | | 477-658 | 457-726 | 394-756 |  |
|  |  |  |  | |  |  |  |  |
| **Female** | n | 81 | 44 | | 3 | 28 | 6 | 0.846 |
|  | Median  (cells/µL) | 595 | 629 | | 553 | 564 | 529 |  |
|  | IQR  (cells/µL) | 480-757 | 487-740 | | 515-650 | 476-804 | 475-602 |  |
|  |  |  |  | |  |  |  |  |
| **Non-MSM^** | n | 95 | 51 | | 10 | 27 | 7 | 0.573 |
|  | Median  (cells/µL) | 549 | 549 | | 582 | 516 | 704 |  |
|  | IQR  (cells/µL) | 440-704 | 445-705 | | 479-686 | 405-688 | 529-868 |  |
|  |  |  |  | |  |  |  |  |
| **MSM** | n | 57 | 44 | | 4 | 4 | 5 | 0.488 |
|  | Median  (cells/µL) | 575 | 586 | | 517 | 574 | 383 |  |
|  | IQR  (cells/µL) | 431-695 | 436-736 | | 438-574 | 487-598 | 295-684 |  |

\*Defined as Day 84 +/- 14 days post estimated date of infection.

+Other subtypes include B, G, CRF02\_AG, CRF11\_CPX, recombinant forms A1A2D, A1C, A1CD, A1D, CK, and CD. Volunteers with missing subtype data are not shown in this table.

#IQR, Interquartile range.

^MSM, Men who have sex with men.